Glenmark launches biosimilar of anti-diabetic drug, liraglutide in India

Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, has launched a biosimilar of the popular anti-diabetic drug, liraglutide, for the first time in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI). Priced at around Rs. 100 for a standard dose of mg (per day), this will lower the cost of therapy by approximately 70%, and will be available only under prescription.

Liraglutide belongs to the class of glucagon-like peptide 1 receptor agonist (GLP-1 RA) drugs, which increase glucose-dependent insulin secretion and decrease in appropriate glucagon secretion. It has been approved globally for the management of type 2 diabetes mellitus in adult patients in the United States and the European Union.

“Glenmark is proud to introduce Lirafit, a novel and affordable biosimilar of the drug liraglutide, for the first time in India. Clinical trials have shown that it helps improve glycaemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity.

Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus. With this launch, we have now ventured into the injectable anti-diabetic market taking another significant stride in the diabetes therapy space,” remarked Alok Malik, president and business head - India formulations, Glenmark Pharmaceuticals Ltd.

Liraglutide has a proven efficacy in improving glycaemic control in patients with type 2 diabetes mellitus. Clinical trials on Indian adult patients with type 2 diabetes mellitus over a 24-week period have demonstrated Lirafit to be effective, safe and well-tolerated. The trials also revealed non-inferior efficacy and a safety profile with that of the reference liraglutide.

Additional benefits of liraglutide include effectively lowering glycaemic parameters, weight reduction, and cardiovascular safety in patients with type 2 diabetes mellitus, GLP-1 RA class of drugs and their mechanism of action GLP-1 RA (Glucagon-like peptide-1 receptor agonists) are a group of drugs used in the treatment of type 2 diabetes. GLP-1 RAs are very effective in lowering blood sugar levels. Several trials have demonstrated that GLP-1 RAs reduce cardiovascular risk in patients with type 2 diabetes mellitus and ASCVD or high cardiovascular risk and have beneficial effects on cardio-renal outcomes beyond their blood glucose-lowering effects in type 2 diabetes mellitus patients. Their mechanism of action involves the release of insulin, in the presence of elevated glucose concentrations, thus decreasing glucagon secretion.

GLP-1 RAs are recommended in the treatment guidelines by the American Diabetes Association as well as the American Association of Clinical Endocrinology (AACE) Consensus Statement & European Society of Cardiology for type 2 diabetes mellitus patients with co-morbidities, like established atherosclerotic cardiovascular disease and obesity. The American Diabetes Association (ADA) also recommends GLP1RAs therapy for weight loss & lesser risk of hypoglycaemia in type 2 diabetes mellitus patients. Drugs belonging to this class include liraglutide, semaglutide, and dulaglutide, among others.

Glenmark has a strong legacy of bringing in new, effective, and affordable treatment options for diabetic patients, especially for those suffering from uncontrolled type 2 diabetes. In 2015, Glenmark was the first to launch the DPP4 inhibitor, teneligliptin (Zita Plus and Ziten), followed by a FDC of teneligliptin + metformin (Zita-Met Plus and Ziten-M). Glenmark later introduced remogliflozin (Remo and Remozen), a novel SGLT-2 inhibitor in 2019; and subsequently, its combinations (Remo-V, Remozen-V, Remo MV, and Remozen MV). Glenmark followed that up with the launch of sitagliptin (Sitazit) and its FDCs in 2022. Then came lobeglitazone (LOBG) and additional FDCs of teneligliptin, including its combinations with pioglitazone (Zita Pio), pioglitazone + metformin (Zita-PioMet), dapagliflozin (Zita-D), and dapagliflozin + metformin (Zita DM). Liraglutide (Lirafit), a glucagon-like peptide-1 receptor agonist (GLP-1 RA) is the latest affordable offering from Glenmark, marking its entry into the injectable anti-diabetic market.

As per the ICMR-INDIAB study conducted between October 2008 and December 2020, the overall weighted prevalence of diabetes was 11.4%19. According to IQVIA sales data for the 12-month period ending August 2023 (MAT August 2023), the market for GLP-1 RA in India is estimated to be Rs. 259 crore, with an annual growth of 108% against the corresponding period last year (MAT August 2022). 

Glenmark Pharmaceuticals Limited is a research-led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!